1. A method of treating breast cancer, comprising administering to a patient a metastatic breast cancer that is negative for estrogen receptor (ER), negative for progesterone receptor (PR) and negative for HER-2 (ultimately designated as triple negative), an effective amount of an anti-antibody c-met and taxane. 2. The method of claim 1, further comprising administering to the patient an effective amount of an anti-VEGF antibody. A method for treating breast cancer, comprising administering to a patient an ER-negative, PR-negative and HER2-negative metastatic breast cancer anti-c-met antibody administered at a dose of 10 mg / kg on day 1 and day 15 of the 28-day cycle and paclitaxel, administered at a dose of 90 mg / ms using iv infusion on day 1, day 8 and day 15 of the 28-day cycle. 4. The method according to claim 3, further comprising administering an anti-VEGF antibody at a dose of 10 mg / kg on day 1 and day 15 of the 28-day cycle. The method of claim 1, wherein the anti-c-met antibody and taxane are administered simultaneously. The method of claim 1, wherein the anti-c-met antibody and taxane are administered sequentially in any order. The method of claim 1, wherein administration of an anti-c-met antibody is preceded by administration of a taxane. The method of claim 1 or 3, wherein the anti-c-met antibody is monovalent. The method according to claim 1 or 3, wherein the anti-c-met antibody contains one antigen-binding arm and contains an Fc region, where the Fc region contains the first and second Fc polypeptides, where the first and second Fc polypeptides are complexed and form an Fc region that increases stability the specified fragment of the antibody compared to the Fab molecule containing the specified antigennegative shoulder. 10. The method according to claim 1 or 3, where the anti-c-met antibody is an antibody or a fragment of this antibody,1. Способ лечения рака молочной железы, включающий введение больному метастатическим раком молочной железы, нег
